-The Telegraph New Delhi: International humanitarian agency Medecins Sans Frontieres has filed an application to block US pharmaceutical company Pfizer from obtaining a patent in India for a vaccine against pneumonia and allow Indian vaccine manufacturers to make low-cost versions. The patent opposition moved by MSF has claimed that Pfizer's patent application, which describes methods of conjugating 13 serotypes (strains) of the bacterium Streptococcus pneumoniae into a single carrier vaccine, does not...

-The Times of India NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease. The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction...

-The Telegraph New Delhi: Health experts today criticised a government delay in implementing a proposed daily drug therapy for tuberculosis patients, meant to reduce the risk of relapse after completion of treatment. Although the health ministry had itself last year released TB treatment standards emphasising a move towards daily therapy, virtually all patients treated under the government TB control programme receive thrice-a-week therapy, which carries a higher risk of relapse. A consortium of...

-The Times of India MUMBAI: Here's why drug-resistant tuberculosis (TB) breeds freely in Mumbai: Patients don't get appropriate medication. A new study collating information from eight hospitals and treatment centres across Mumbai, Thane and Navi Mumbai found patients were given drugs that they were resistant to. The study, published in PLOS ONE medical journal recently, looked at 340 patients suffering from multi-drug resistant (MDR) TB between 2005 and 2013. "We found only 29.4% of...

-The Telegraph New Delhi: India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine. The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900...